The future of acne treatment might look a whole lot different than the range of oral and topical medications currently on ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

Acne vulgaris affects a large proportion of adolescents and young adults and can lead to long-term scarring and psychological distress. Its pathogenesis involves excessive sebum production, bacterial ...

Acne vulgaris is a chronic inflammatory skin disorder driven by bacterial overgrowth and persistent inflammation, often requiring combination therapy ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...

Acne vulgaris on the back of a healthy 13-year-old boy A dermatologist explores dealing with increasing bacterial resistance and selecting the treatment that minimizes irritation and other skin ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne drug denifanstat (ASC40). Read more here.

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...